Yang J, Kang H, Lyu L, Xiong W, Hu Y. A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov. Discov Oncol. 2023;14:151.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hwangbo H, Patterson SC, Dai A, Plana D, Palmer AC. Additivity predicts the efficacy of most approved combination therapies for advanced cancer. Nat Cancer. 2023;4:1693–704.

Article  CAS  PubMed  Google Scholar 

Beaver JA, Pazdur R. The wild west of checkpoint inhibitor development. N Engl J Med. 2022;386:1297–301.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency. Guideline on the clinical evaluation of anticancer medicinal products. November 18, 2023. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-anticancer-medicinal-products-revision-6_en.pdf

Olivier T, Haslam A, Prasad V. Dose modification rules and availability of growth factor support: a cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021. Eur J Cancer. 2022;172:349–56.

Article  CAS  PubMed  Google Scholar 

ICH S9 Non-clinical evaluation for anticancer pharmaceuticals - Scientific guideline. May 16, 2018. https://www.ema.europa.eu/system/files/documents/scientific-guideline/wc500248965_en.pdf

Muller PY, Milton MN. The determination and interpretation of the therapeutic index in drug development. Nat Rev Drug Discov. 2012;11:751–61.

Article  CAS  PubMed  Google Scholar 

Hansen AR, Cook N, Amir E, Siu LL, Abdul Razak AR. Determinants of the recommended phase 2 dose of molecular targeted agents. Cancer. 2017;123:1409–15.

Article  CAS  PubMed  Google Scholar 

Fraisse J, Dinart D, Tosi D, Bellera C, Mollevi C. Optimal biological dose: a systematic review in cancer phase I clinical trials. BMC Cancer. 2021;21:60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

FDA Guidance for Industry. Expansion Cohorts: Use in First-in-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics. March, 2022. https://www.fda.gov/media/115172/download

NCT07000149 | A Study to Investigate the Eficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC | ClinicalTrials.gov

Liu S, Nikanjam M, Kurzrock R. Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. Oncotarget. 2016;8(7):11310–20.

Article  Google Scholar 

Zhou L, Reddy MB, Mittapalli RK, Yang J, Yin D. Oncology combination dose-finding study design for targeted and immuno-oncology therapies. Clin Pharmacol Ther. 2024;115:29–35.

Article  CAS  PubMed  Google Scholar 

Ananthakrishnan R, Lin R, He C, Chen Y, Li D, LaValley M. An overview of the BOIN design and its current extensions for novel early-phase oncology trials. Contemp Clin Trials Commun. 2022;28:100943.

Article  PubMed  PubMed Central  Google Scholar 

Zhou H, Yuan Y, Nie L. Accuracy, safety, and reliability of novel phase I trial designs. Clin Cancer Res. 2018;24:4357–64.

Article  PubMed  Google Scholar 

Zhou Y, Lin R, Lee JJ, Li D, Wang L, Li R, et al. TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Stat Med. 2022;41:1918–31.

Article  PubMed  PubMed Central  Google Scholar 

Tighiouart M, Liu Y, Rogatko A. Escalation with overdose control using time to toxicity for cancer phase I clinical trials. PLoS One. 2014;9:e93070.

Article  PubMed  PubMed Central  Google Scholar 

Jiménez JL, Zheng H. A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages. Biom J. 2023;65:e2200288.

Article  PubMed  PubMed Central  Google Scholar 

FDA Guidance for Industry. Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases. August, 2024. https://www.fda.gov/media/164555/download

FDA Draft Guidance for Industry: Master Protocols for Drug and Biological Product Development. December, 2023. https://www.fda.gov/media/174976/download

Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019;20:572.

Article  PubMed  PubMed Central  Google Scholar 

Ko AH, Kim KP, Siveke JT, Lopez CD, Lacy J, O’Reilly EM, et al. Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric cancer: MORPHEUS phase Ib/II umbrella randomized study platform. Oncologist. 2023;28:553-e472.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Finn RS, Ryoo BY, Hsu CH, Li D, Burgoyne AM, Cotter C, et al. Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study. Lancet Oncol. 2025;26:214–26.

Article  CAS  PubMed  Google Scholar 

FDA Draft Guidance for Industry. Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval. 2026 https://www.fda.gov/media/190647/download

Rosner B. Fundamentals of Biostatistics. 7th ed. Boston, MA: Brooks/Cole; 2011.

Google Scholar 

FDA Guidance for Industry. Optimizing the Dosage of Human P rescription Drugs and Biological Products for the Treatment of Oncologic Diseases. August, 2024 . https://www.fda.gov/media/164555/download

FDA Oncologic Drugs Advisory Committee Meeting on Durvalumab. July 17, 2025. https://www.fda.gov/media/187578/download

Wang X, Chen M, Chu S, Fan R, Chan ISF. A rank-based approach to improve the efficiency of inferential seamless phase 2/3 clinical trials with dose optimization. Contemp Clin Trials. 2023;132:107300.

Article  PubMed  Google Scholar 

FDA Oncology Dosing Tool Kit. May 10, 2023: https://www.fda.gov/about-fda/oncology-center-excellence/oncology-dosing-tool-kit

Cheng Y, Chu S, Pu J, Chen M, Hong K, Maciag P, et al. Exposure-response-based multiattribute clinical utility score framework to facilitate optimal dose selection for oncology drugs. J Clin Oncol. 2024;3:JCO2400349.

Google Scholar 

Richardson NC, Kasamon Y, Pazdur R, Gormley N. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol. 2022;23:563–6.

Article  CAS  PubMed  Google Scholar 

FDA Draft Guidance for Industry: Approaches to Assessment of Overall Survival in Oncology Clinical Trials. August, 2025. https://www.fda.gov/media/188274/download

Borad MJ, Curtis KK, Babiker HM, Benjamin M, Tibes R, Ramanathan RK, et al. The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials. J Cancer. 2012;3:345–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang JC, Shepherd FA, Kim DW, Lee GW, Lee JS, Chang GC, et al. Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL brief report. J Thorac Oncol. 2019;14:933–9.

Article  PubMed  Google Scholar 

Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020;31:507–16.

Article  CAS  PubMed  Google Scholar 

FDA Guidance for Industry. Codevelopment of Two or More New Investigational Drugs for Use in Combination. June, 2013. https://www.fda.gov/media/80100/download

FDA Draft Guidance for Industry. Development of Cancer Drugs for Use in Novel Combination – Determining the Contribution of the Individual Drugs’ Effects. Guidance Ind July, 2025. https://www.fda.gov/media/187589/download

Brewer JR, Chang E, Agrawal S, Singh H, Suzman DL, Xu J, et al. Regulatory considerations for contribution of effect of drugs used in combination regimens: renal cell cancer case studies. Clin Cancer Res. 2020;26:6406–11.

Article  PubMed  Google Scholar 

Ebraheem MS, Chakraborty R, Rochwerg B, Visram A, Mohyuddin GR, Venner CP, et al. Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2024;8:5993–6002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e890–901.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P. PERSEUS Trial Investigators. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;390:301–313.

Workshop FDA-AACR. How Much is Enough? Trial Designs for Treatment Regimens with Multip